Trials / Terminated
TerminatedNCT03155932
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD334 | APD334 active treatment for 24 weeks. |
Timeline
- Start date
- 2017-12-29
- Primary completion
- 2019-01-31
- Completion
- 2019-01-31
- First posted
- 2017-05-16
- Last updated
- 2022-03-24
- Results posted
- 2022-03-24
Locations
9 sites across 3 countries: United States, Australia, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03155932. Inclusion in this directory is not an endorsement.